|

Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver

RECRUITINGN/ASponsored by Yunnan Cancer Hospital
Actively Recruiting
PhaseN/A
SponsorYunnan Cancer Hospital
Started2023-12-25
Est. completion2024-12-30
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06735118

Summary

The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment. The main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

1. CT/B ultrasound showed no fatty liver
2. No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia
3. Received neoadjuvant/adjuvant chemotherapy

Exclusion Criteria:

1. Missing follow-up information
2. Liver lesions (metastases, hemangioma, etc.)
3. Poor image quality

Conditions2

Liver DiseaseNon Alcoholic Fatty Liver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.